E-LIB Suche - Ergebnisse für: Shitara, K

1

Corrigendum to "Comprehensive clinical and molecular charac..:

Kubota, Y. ; Kawazoe, A. ; Mishima, S....
ESMO Open. 9 (2024) 1 - p. 102232 , 2024

Link: https://doi.org/10.1016/..

2

495TiP CLARITY-Gastric 01: A randomised phase III study of ..:

Shitara, K. ; Janjigian, Y.Y. ; Elimova, E....
Annals of Oncology. 35 (2024) - p. S196-S197 , 2024

Link: https://doi.org/10.1016/..

3

Safety and efficacy of perioperative FLOT regimen in Japane..:

Takei, S. ; Kawazoe, A. ; Jubashi, A....
ESMO Gastrointestinal Oncology. 4 (2024) - p. 100050 , 2024

Link: https://doi.org/10.1016/..

4

Clinical implementation of simultaneous multiple biomarkers..:

Okazaki, U. ; Nakayama, I. ; Sakamoto, N....
ESMO Gastrointestinal Oncology. 5 (2024) - p. 100086 , 2024

Link: https://doi.org/10.1016/..

5

Pan-Asian adapted ESMO Clinical Practice Guidelines for the..:

Shitara, K. ; Fleitas, T. ; Kawakami, H....
ESMO Open. 9 (2024) 2 - p. 102226 , 2024

Link: https://doi.org/10.1016/..

6

LBA3 Final analysis of the phase III KEYNOTE-585 study of p..:

Shitara, K. ; Rha, S.Y. ; Wyrwicz, L.S....
Annals of Oncology. 35 (2024) - p. S213 , 2024

Link: https://doi.org/10.1016/..

7

500TiP An open label phase Ib/II study of trastuzumab derux..:

Aoki, Y. ; Nakayama, I. ; Fukuoka, S....
Annals of Oncology. 35 (2024) - p. S199 , 2024

Link: https://doi.org/10.1016/..

8

267MO Pooled analysis of trastuzumab deruxtecan (T-DXd) ret..:

Rugo, H.S. ; Tokunaga, E. ; Iwata, H....
ESMO Open. 9 (2024) - p. 103326 , 2024

Link: https://doi.org/10.1016/..

9

419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as fi..:

Wyrwicz, L.S. ; Shitara, K. ; Moehler, M....
Annals of Oncology. 35 (2024) - p. S169-S170 , 2024

Link: https://doi.org/10.1016/..

10

Comparative efficacy of PD-1 blockade in patients with dMMR..:

Mazzoli, G. ; Nichetti, F. ; Shitara, K....
ESMO Gastrointestinal Oncology. 3 (2024) - p. 100037 , 2024

Link: https://doi.org/10.1016/..

11

501TiP Valemetostat and trastuzumab deruxtecan (T-DXd) in p..:

Shitara, K. ; Enzinger, P.C. ; Mohapatra, A.S..
Annals of Oncology. 35 (2024) - p. S200 , 2024

Link: https://doi.org/10.1016/..

12

Comprehensive clinical and molecular characterization of cl..:

Kubota, Y. ; Kawazoe, A. ; Mishima, S....
ESMO Open. 8 (2023) 1 - p. 100762 , 2023

Link: https://doi.org/10.1016/..

13

Association of PD-L1 and PD-L2 expression and tumor-infiltr..:

Imai, M. ; Nakamura, Y. ; Denda, T....
ESMO Gastrointestinal Oncology. 2 (2023) - p. 100008 , 2023

Link: https://doi.org/10.1016/..

14

ARCAD-Asia initiative: leveraging yesterday's data for tomo..:

Takeda, Y. ; Misumi, T. ; Bando, H....
ESMO Gastrointestinal Oncology. 2 (2023) - p. 100007 , 2023

Link: https://doi.org/10.1016/..

15

Pooled safety analysis from phase III studies of trifluridi..:

Van Cutsem, E. ; Hochster, H. ; Shitara, K....
ESMO Open. 7 (2022) 6 - p. 100633 , 2022

Link: https://doi.org/10.1016/..